Medeiros GC, Matheson M, Demo I, Reid MJ, Matheson S, Twose C, Smith GS, Gould TD, Zarate CA Jr, Barrett FS, Goes FS. Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies. Lancet Psychiatry. 2023 Aug 22:S2215-0366(23)00183-9. doi: 10.1016/S2215-0366(23)00183-9. Epub ahead of print. PMID: 37625426.
Hess EM, Venniro M, Gould TD. Relative to females, male rats are more willing to forego obtaining sucrose reward in order to prevent harm to their cage mate. Psychopharmacology (Berl). 2023 Aug 2. doi: 10.1007/s00213-023-06435-2. Epub ahead of print. PMID: 37530881.
Brown KA, Gould TD. Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipient. Neuropsychopharmacology. 2023 Jul 24. doi: 10.1038/s41386-023-01675-4. Epub ahead of print. PMID: 37488279.
Quintanilla B, Medeiros GC, Greenstein D, Yuan P, Johnston JN, Park LT, Goes FS, Gould TD, Zarate CA Jr. κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine. J Clin Psychopharmacol. 2023 Mar-Apr 01;43(2):89-96.
Hess EM, Gould TD. Possible psychedelic therapeutic mechanism. Science. 2023 Feb 17;379(6633):642-643. doi: 10.1126/science.adg2989. Epub 2023 Feb 16.
Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA Jr, Thompson SM, Gould TD. NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. J Neurosci. 2023 Jan 3:JN-RM-1316-22.
Brown KA, Zanos P, Powels CF, Fix CJ, Michaelides M, Pereira EFR, Moaddel R, Gould TD. Ketamine preservative benzethonium chloride potentiates hippocampal synaptic transmission and binds neurotransmitter receptors and transporters. Neuropharmacology. 2023 Mar 1;225:109403.
Georgiou P, Zanos P, Mou TM, An X, Gerhard DM, Dryanovski DI, Potter LE, Highland JN, Jenne CE, Stewart BW, Pultorak KJ, Yuan P, Powels CF, Lovett J, Pereira EFR, Clark SM, Tonelli LH, Moaddel R, Zarate CA Jr, Duman RS, Thompson SM, Gould TD. Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor. Nat Neurosci. 2022 Aug 30.
Riggs LM, Thompson SM, Gould TD. (2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity. Neuropharmacology. 2022 Aug 15;214:109153.
Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez-Soto M, Morris PJ, Moaddel R, Kang HJ, Zanos P, Gould TD, Thomas CJ, Sibley DR, Zarate CA Jr, Michaelides M. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Mol Psychiatry. 2022 Jun 29.
Medeiros GC, Gould TD, Prueitt WL, Nanavati J, Grunebaum MF, Farber NB, Singh B, Selvaraj S, Machado-Vieira R, Achtyes ED, Parikh SV, Frye MA, Zarate CA Jr, Goes FS. Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Mol Psychiatry. 2022 Jun 27.
Hasin N, Riggs LM, Shekhtman T, Ashworth J, Lease R, Oshone RT, Humphries EM, Badner JA, Thomson PA, Glahn DC, Craig DW, Edenberg HJ, Gershon ES, McMahon FJ, Nurnberger JI, Zandi PP, Kelsoe JR, Roach JC, Gould TD, Ament SA. Rare variants implicate NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder. Mol Psychiatry. 2022 May 11.
Moaddel R, Zanos P, Farmer CA, Kadriu B, Morris PJ, Lovett J, Acevedo-Diaz EE, Cavanaugh GW, Yuan P, Yavi M, Thomas CJ, Park LT, Ferrucci L, Gould TD, Zarate CA Jr. Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. Transl Psychiatry. 2022 May 2;12(1):179.
Hess EM, Riggs LM, Michaelides M, Gould TD. Mechanisms of ketamine and its metabolites as antidepressants. Biochem Pharmacol. 2022 Mar;197:114892.
Highland JN, Morris PJ, Konrath KM, Riggs LM, Hagen NR, Zanos P, Powels CF, Moaddel R, Thomas CJ, Wang AQ, Gould TD. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines. ACS Chem Neurosci. 2022 Feb 16;13(4):510-523. doi: 10.1021/acschemneuro.1c00761.
Highland JN, Farmer CA, Zanos P, Lovett J, Zarate CA Jr, Moaddel R, Gould TD. Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans. J Psychopharmacol. 2022 Feb;36(2):170-182. doi: 10.1177/02698811211064922.
Troppoli TA, Zanos P, Georgiou P, Gould TD, Rudolph U, Thompson SM. Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. Biol Psychiatry. 2021 Dec 15:S0006-3223(21)01839-4.
Riggs LM, An X, Pereira EFR, Gould TD. (R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. Transl Psychiatry. 2021 Nov 12;11(1):583.
Morris PJ, Burke RD, Sharma AK, Lynch DC, Lemke-Boutcher LE, Mathew S, Elayan I, Rao DB, Gould TD, Zarate CA Jr, Zanos P, Moaddel R, Thomas CJ. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicol Teratol. 2021 Sep-Oct;87:106993.
Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, Moaddel R, Thomas CJ, Zarate CA Jr, Pereira EFR, Gould TD. Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. Pharmacol Rev. 2021 Apr;73(2):763-791.
Riggs LM, Gould TD. Ketamine and the Future of Rapid-Acting Antidepressants. Annu Rev Clin Psychol. 2021 Feb 9.
Medeiros GC, Greenstein D, Kadriu B, Yuan P, Park LT, Gould TD, Zarate CA Jr. Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. 2021 Feb 1;280(Pt A):136-139.
Elmer GI, Tapocik JD, Mayo CL, Zanos P, Gould TD. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. Pharmacol Biochem Behav. 2020 Sep;196:172973.
Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, Nugent AC, Kadriu B, Yuan P, Gould TD, Park LT, Zarate CA Jr. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020 Jul;45(8):1398-1404
Park LT, Kadriu B, Gould TD, Zanos P, Greenstein D, Evans JW, Yuan P, Farmer CA, Oppenheimer M, George JM, Adeojo LW, Snodgrass HR, Smith MA, Henter ID, Machado-Vieira R, Mannes AJ, Zarate CA. A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2020 Jul 29;23(7):417-425.
Potter LE, Zanos P, Gould TD. Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators. Neuron. 2020 Jan 8;105(1):1-3. doi: 10.1016/j.neuron.2019.12.011.
Krimmel SR, Zanos P, Georgiou P, Colloca L, Gould TD. Classical conditioning of antidepressant placebo effects in mice. Psychopharmacology (Berl). 2020 Jan;237(1):93-102.
Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology. 2020 Jan;45(2):426-436.
Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol. 2019 Jul;176(14):2573-2592.
Highland JN, Zanos P, Georgiou P, Gould TD. Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology. 2019 Sep;44(10):1788-1796.
Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450.
Georgiou P, Zanos P, Jenne CE, Gould TD. Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation. Front Psychiatry. 2019 Feb 26;10:81.
Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169.
Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA Jr, Thomas CJ, Moaddel R, Gould TD. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. J Psychopharmacol. 2019 Jan;33(1):12-24.
Gould TD, Zarate CA Jr, Thompson SM. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236.
Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. 2019 Jul;24(7):1040-1052.
Jarvela TS, Womack T, Georgiou P, Gould TD, Eriksen JL, Lindberg I (2018) 7B2 chaperone knockout in APP model mice results in reduced plaque burden. Sci Rep. 2018 Jun 28;8(1):9813.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacol Rev. 2018 Jul;70(3):621-660.
Royal W 3rd, Can A, Gould TD, Guo M, Huse J, Jackson M, Davis H, Bryant J (2018) Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats. J Neurovirol. 2018 Apr;24(2):246-253.
Brown PL, Zanos P, Wang L, Elmer GI, Gould TD, Shepard PD (2018) Isoflurane but not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression? Int J Neuropsychopharmacol. 2018 Mar 15. doi: 10.1093/ijnp/pyy029
Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018 Mar 13.
Zanos P, Thompson SM, Duman RS, Zarate CA Jr., Gould TD (2018) Convergent mechanisms underlying rapid antidepressant action. CNS Drugs. Mar 7.
Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr (2018) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. Feb 27.
Zarate CA, Gould TD, Thompson SM (2018) Ketamine and other rapid-acting antidepressants: A new insight into the biology of mood disorders. Annual Review of Pharmacology and Toxicology 58 (1).
Zanos P, Gould TD (2018) Intracellular signaling pathways involved in (S)- and (R)-ketamine antidepressant actions. Biol Psychiatry. Jan 1;83(1):2-4.
Georgiou P, Zanos P, Bhat S, Tracy JK, Merchenthaler IJ, McCarthy MM, Gould TD (2018) Dopamine and stress system modulation of sex differences in decision making. Neuropsychopharmacology. Jan;43(2):313-324.
Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ. (2017) Synthesis and N-Methyl-d-aspartate (NMDA) receptor activity of ketamine metabolites. Org Lett. Sep 1;19(17):4572-4575.
Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT (2017) Animal models to improve our understanding and treatment of suicidal behavior. Translational Psychiatry. Apr 11;7(4):e1092.
Terrillion CE, Dao DT, Cachope R, Lobo MK, Puche AC, Cheer JF, Gould TD (2017) Reduced levels of Cacna1c attenuate mesolimbic dopamine system function. Genes, Brain and Behavior. Jun;16(5):495-505.
Terrillion CE, Francis TC, Puche AC, Lobo MK, Gould TD (2017) Decreased nucleus accumbens expression of psychiatric disorder risk gene cacna1c promotes susceptibility to social stress. International Journal of Neuropsychopharmacology. May 1;20(5):428-433.
Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM (2017) A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro. Mar 7;4(1). pii: ENEURO.0285-16.2017.
Le NT, Chang L, Kovlyagina I, Georgiou P, Safren N, Braunstein KE, Kvarta MD, Van Dyke AM, LeGates TA, Philips T, Morrison BM, Thompson SM, Puche AC, Gould TD, Rothstein JD, Wong PC, Monteiro MJ (2017) Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. Proceedings of the National Academy of Sciences. 2016 Nov 22;113(47):E7580-E7589.
Can A, Frost DO, Cachope R, Cheer JF, Gould TD (2016) Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens. Journal of Neurochemistry. Nov;139(4):576-585.
Zhang Y, Zanos P, Jackson I, Zhang X, Zhu X, Gould TD, Vujaskovic Z (2016) Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. International Journal of Radiation Oncology. Oct 1;96(2):E474.
Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD (2016) Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. Journal of Pharmacology and Experimental Therapeutics. Oct;359(1):159-70.
Zanos P, Moaddel R, Alkondon M, Morris PJ, Elmer GI, Yuan P, Fischell J, Pribut HJ, Georgiou P, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Wainer IW, Zarate CA Jr, Gould TD (2016) Ketamine exerts NMDAR-independent antidepressant actions responsible for therapeutic effects. Nature. 533, 481-486.
Kop WJ, Galvao TF, Synowksi SJ, XU W, Can A, O’Shea KM, Gould TD, Stanley WC (2015) Effects of environmental stress following myocardial infarction on behavioral measures and heart failure progression: The influence of isolated and group housing conditions. Physiology and Behavior. 152, 168-174.
Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA Jr, Schwarcz R, Gould TD (2015) The prodrug 4-chlorokynurenine causes ketamine-like antidepressant, but not side effects, by NMDA/glycineB-site inhibition. Journal of Pharmacology and Experimental Therapeutics. 355. 76-85.
Prokai L, Nguyen V, Szarka1 S, Garg P, Sabnis G, Bimonte-Nelson HA, McLaughlin KJ, Talboom JS, Conrad CD, Brodie A, Gould TD, Koulen P, Merchenthaler I, Prokai-Tatrai K (2015) The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders. Science Translational Medicine. 297ra113.
Zanos P, Bhat S, Smith RJ, , Terrillion CE, Tonelli LH, Gould TD (2015) Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav1.2). European Journal of Neuroscience. 42. 2499-2507.
Lee R, Pirooznia M, Guintivano J, Ly M, Ewald ER, Tamashiro KL, Gould TD, Moran TH, Potash JB (2015) Search for common targets of lithium and valproic acid identifies shared epigenetic regulation of the rat leptin receptor gene. Translational Psychiatry. 5e600.
Pezzato FA, Can A, Horta JAC, Mijares MG, Gould TD (2015) Effects of lithium on behavioral dysinhibition induced by median raphe nucleus lesion. Psychopharmacology. 232, 1441-1450.
Clark SM, Sand J, Francis TC, Nagaraju A, Michael KC, Keegan AD, Kusnecov A, Gould TD, Tonelli LH (2014) Immune status influences behavioral resilience in mouse models of posttraumatic stress. Brain, Behavior, and Immunity. 38, 192-201.
Safren N, Ayadi AE, Chang L, Terrillion CE, Gould TD, Boehning DF, Monteiro MJ (2014) Ubiquilin-1 overexpression increases the lifespan and delays accumulation of huntingtin aggregates in the R6/2 mouse model of Huntington’s disease. PLoS ONE. 9, e87513.
Can A, Schulze TG, Gould TD (2014) Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacology, Biochemistry, and Behavior. 123, 3-16.
Guintivano J, Arad M, Gould TD, Payne J, Kaminsky Z (2014) Antenatal blood DNA methylation biomarkers prospectively predict post partum depression. Molecular Psychiatry. 19,560-567.
Halcomb M, Gould TD, Grahame N (2013) Lithium, but not valproate, reduces impulsive choice in the delay discounting task in mice. Neuropsychopharmacology. 38, 1937-1944.
Can A, Piantadosi SC, Gould TD (2013) Stability of antidepressant-like response to lithium administration in mice: effects of genetics, sex, and maternal care. Psychopharmacology. 228, 411-418.
Guintivano J, Arad M, Gould TD, Kaminsky Z (2013) BioTile, a Perl based tool for the identification of differentially methylated regions in tiling microarray data. BMC Bioinformatics. 14, 76.
Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM., Gould TD (2012) CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Progress in Neurobiology. 9, 1-14.
Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD (2012) The mouse tail suspension test. Journal of Visualized Experiments. 59, e3769.
Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD (2012) The mouse forced swim test. Journal of Visualized Experiments. 59, e3638.
Can A, Grahame NJ, Gould TD (2012) Affect-related behaviors in mice selectively bred for high and low voluntary alcohol consumption. Behavior Genetics. 42, 313-322.
Courtet P, Gottesman II, Jollant F, Gould TD (2011) The neuroscience of suicidal behaviors: what can we expect from endophenotype strategies? Translational Psychiatry. 1e7.
Can A, Blackwell RA, Piantadosi SC, Dao DT, O’Donnell KC, Gould TD (2011) Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes, Brain, and Behavior. 10, 434-443.
Kas MJH, Krishnan V, Gould TD, Collier DA, Olivier B, Lesch KP, Domenici, E, Fuchs E, Gross C, Castern E (2011) Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders. European Neuropsychopharmacology. 21, 532-544.
Dao DT, Mahon PB, Cai X, Kovacsics CE, Blackwell RA, Arad M, Shi J, Zandi PP, O’Donnell P, Bipolar Genome Study (BiGS) Consortium, Knowles JA, Weissman MM, Coryell W, Scheftner WA, Lawson WB, Levinson DF, Thompson SM, Potash JB, Gould TD (2010) Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biological Psychiatry. 68, 801-810.
Kovacsics CE, Gould TD (2010) Shock-induced aggression in mice is modified by lithium. Pharmacology, Biochemistry and Behavior. 94, 380-386.
Tonelli LH, Katz M, Kovacsics CE, Gould TD, Joppy B, Hoshini A, Hoffman G, Komarow H, Postolache TT (2009) Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. Brain, Behavior, and Immunity. 23, 784-793.
Kovacsics CE, Gottesman II, Gould TD (2009) Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annual Review of Pharmacology and Toxicology. 49, 175-198.
Kovacsics CE, Goyal HK, Thomas KJ, Gould TD (2008) The antisuicidal effects of lithium: a review of the clinical literature and underlying pharmacology. International Journal of Child Health and Human Development. 1, 225-244.
Gould TD, O’Donnell KC, Picchini AM, Dow ER, Chen G, Manji HK (2008) Generation and behavioral characterization of beta-catenin forebrain-specific knockout mice. Behavioural Brain Research. 189, 117-125.
Gould TD, O’Donnell KC, Dow ER, Chen G, Manji HK (2008) Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology. 54, 577-587.
O’Donnell KC and Gould TD (2007) The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neuroscience and Biobehavioral Reviews. 31, 932-962.
Gould TD and Manji HK (2007) Targeting neurotrophic signal transduction pathways in the treatment of mood disorders. Current Signal Transduction Therapy. 2, 101-110.
Gould TD, Dow ER, O’Donnell KC, Chen G, Manji HK (2007) Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS & Neurological Disorders - Drug Targets. 6, 193-204.
Gould NF, Holmes MK, Fantie BD, Luckenbaugh DA, Pine DS, Gould TD, Burgess N, Manji HK, Zarate CA (2007) Performance on a virtual reality spatial memory task in depressed patients. The American Journal of Psychiatry. 164, 516-519.
Gould TD, O’Donnell KC, Picchini AM, Manji HK (2007) Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology. 32, 1321-1333.
Gould TD, Einat H, O’Donnell KC, Picchini AM, Schloesser RS, Manji HK (2007) Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology. 32, 2173-2183.
Gould TD (2006) Targeting glycogen synthase kinase-3 as an approach to develop novel mood stabilizing medications. Expert Opinion on Therapeutic Targets. 10, 377-392.
Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Current Drug Targets. 7, 1399-1410.
Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK (2006) Toward constructing an endophenotype strategy for bipolar disorders. Biological Psychiatry. 60, 93-105.
Gould TD and Gottesman II (2006) Psychiatric endophenotypes and the development of valid animal models. Genes, Brain, and Behavior. 5, 113-119.
Bachmann RF, Schloesser RJ, Gould TD, Manji HK (2005) Molecular and cellular neurobiological studies identify novel targets for the long-term actions of mood stabilizers. Clinical Approaches in Bipolar Disorders. 4, 46-55.
Gould TD and Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 30, 1223-1237.
Bachmann RF, Schloesser RJ, Gould TD, Manji HK (2005) Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Molecular Neurobiology. 32, 173-202.
Picchini AM, Manji HK, Gould TD (2004) GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders? Drug Discovery Today: Disease Mechanisms. 1, 419-428.
Quiroz JA, Gould TD, Manji HK (2004) Molecular effects of lithium. Molecular Interventions. 4, 259-272.
Gould TD, Einat H, Bhat R, Manji HK (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. International Journal of Neuropsychopharmacology. 7, 387-390.
Gould TD and Manji HK (2004) The molecular medicine revolution in psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. Journal of Clinical Psychiatry. 65, 598-604.
Hao YL, Creson T, Zhang L, Li PP, Du F, Yuan P, Gould TD, Manji HK, Chen G (2004) Mood-stabilizer valproate promotes ERK pathway dependent cortical neuronal growth and neurogenesis. The Journal of Neuroscience. 24, 6590-6599.
Yuan P, Gould TD, Gray NA, Bachmann RF, Schloesser RJ, Lan M, Du J, Moore GJ, Manji HK (2004) Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications. Clinical Neuroscience Research. 4, 137-153.
Gould TD, Quiroz, JA, Singh J, Zarate CA, Manji HK (2004) Emerging experimental treatments for bipolar disorder: insight from the molecular and cellular actions of current mood stabilizers*. Molecular Psychiatry. 8, 734-755. *cover photo from issue
Quiroz, JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK (2004) Emerging experimental treatments for bipolar disorder: clues from the molecular pathophysiology. Molecular Psychiatry. 8, 756-776.
Gould TD, Zarate CA, Manji HK (2004) Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Journal of Clinical Psychiatry. 65, 10-21.
Gould TD, Chen G, Manji HK (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 29, 32-38.
Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood-modulation. The Journal of Neuroscience. 23, 7311-7316.
Gould TD, Gray NA, Manji HK (2003) Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacological Research. 48, 49-53.
Li J, Gould TD, Yuan P, Manji HK, Chen G (2003) Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology. 28, 1017-1025 [Erratum in: Neuropsychopharmacology (2003) 28, 1219].
Einat H, Manji HK, Gould TD, Du J, Chen G (2003) Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News & Perspectives. 16, 453-463.
Manji HK, Gottesman II, Gould TD (2003) Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Science STKE. Pe49.
Gottesman II and Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. The American Journal of Psychiatry. 160, 636-645.
Gould TD, Chen G, Manji HK (2002) Mood stabilizer psychopharmacology. Clinical Neuroscience Research. 2, 193-212.
Gould TD and Manji HK (2002) Signaling pathways in the pathophysiology of mood disorders. Journal of Psychosomatic Research. 53, 687-697.
Gould TD and Manji HK (2002) The Wnt signaling pathway in bipolar disorder. The Neuroscientist. 8, 497-511.
Lenox RH, Gould TD, Manji HK (2002) Endophenotypes in bipolar disorder. American Journal of Medical Genetics: Neuropsychiatrics Genetics. 114, 391-406 [Erratum in: Am J Med Genet (2002) 114, 592].
Gould TD, Bastain TM, Israel ME, Hommer DW, Castellanos FX (2001) Altered performance on an ocular fixation task in attention-deficit/hyperactivity disorder. Biological Psychiatry. 50, 633-635.
Gould TD and Pfeifer K (1998) Imprinting of mouse Kvlqt1 is developmentally regulated. Human Molecular Genetics. 7, 483-487.
Drazinic CM, Szabo ST, Gould TD, Manji HK (2017) Neurotransmitters and receptors in psychiatric disorders. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 5th edition, Schatzberg AF, Nemeroff CB editors, American Psychiatric Publishing, Washington, DC, pp 45-116.
Shim SS, Gould TD (2010) Neuroprotective and neurotrophic actions of lithium: implications for the treatment of bipolar disorder, Alzheimer's disease and neurodegenerative disorders. In: Metals and Neurodegeneration, Huang S editor, Research Signpost, Kerala, India, pp 231-268.
Gould TD, Dao DT, Kovacsics CE (2009) The open field test. In: Mood and Anxiety Related Phenotypes in Mice: characterization using behavioral tests, Gould TD editor, The Humana Press Inc., Totowa, NJ, pp 1-20.
Szabo ST, Gould TD, Manji HK (2009) Introduction to neurotransmitters, receptors, signal transduction, and second messengers. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th edition, Schatzberg AF, Nemeroff CB editors, American Psychiatric Publishing, Washington, DC, pp 3-58.
Gould TD, O’Donnell KC, Manji HK (2006) Glycogen synthase kinase-3: a target for the development of novel treatments for mania. In: New Developments in Mania Research, Kotlar MB editor, Nova Science Publishers, Inc., Hauppauge, NY, pp 135-159.
Gould TD and Manji HK (2006) Glycogen synthase kinase-3: a target for novel mood disorder treatments. In: Glycogen Synthase Kinase-3 (GSK-3) and its Inhibitors: Drug Discovery and Development, Marinez A, Castro A, Medina M editors, John Wiley & Sons, Inc., Hoboken, NJ, pp 125-154.
Quiroz JA, Szabo ST, Gould TD, Zarate CA Jr, Manji HK (2006) The intracellular neurobiology as a future challenge for the psychopharmacology. In: History of Psychopharmacology, 2nd Edition, F. López-Muñoz, C. Alamo editors, Editorial Medica Panamericana, Madrid, Spain, pp 273-330.
Singh J, Quiroz JA, Gould TD, Zarate CA, Manji HK (2006) The molecular and cellular neurobiology of severe mood disorders. In: The American Psychiatric Publishing Textbook of Mood Disorders, Stein DJ, Kupfer DJ, Schatzberg AF editors, American Psychiatric Publishing, Inc., Arlington, VA, pp 197-218.
Yuan P, Zhou R., Farzad N, Gould TD, Gray NA, Du J, Manji HK (2005) Enhancing resilience to stress: the role of signaling cascades. In: Handbook of Stress and the Brain: Part 1, The Neurobiology of Stress, Steckler T, Kalin N, Reul JMHM editors, Elsevier Science Publication Company, San Diego, CA, pp 751-771.
Gottesman II, Gould TD (2004) The endophenotype concept in psychiatry: etymology and strategic intentions. In: Research Advances in Genetics and Genomics: Implications for Psychiatry. Andreasen NC editor, American Psychiatric Publishing, Inc., Arlington, VA, pp 63-84 [Reprint of # 7 above].
Payne JL, Quiroz J, Gould TD, Zarate CA, Manji HK (2003) Neurobiology of bipolar disorder. In: Neurobiology of Mental Illness, 2nd edition, Charney DS, Nestler EJ editors, Oxford University Press, New York, NY, pp 397-420.
Du J, Gould TD, Manji HK (2003) Neurotrophic signaling in mood disorders. In: Signal Transduction and Human Disease, Finkel T, Gutkind JS, Wiley-Interscience editors, Hoboken, New Jersey, pp 411-445.
Szabo ST, Gould TD, Manji HK (2003) Introduction to neurotransmitters, receptors, signal transduction, and second messengers. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd edition, Schatzberg AF, Nemeroff CB editors, American Psychiatric Publishing, Washington, DC, pp 3-52.
Manji HK, Quiroz J, Gould TD (2003) Cellular resilience and neuroplasticity in mood disorders. Psychiatric Times. January, pp 55-59.
Gould TD, Gray NA, Manji HK (2003) The cellular neurobiology of severe mood and anxiety disorders: implications for the development of novel therapeutics. In: Molecular Neurobiology for the Clinician; APA Review of Psychiatry Series, Charney DS editor, Oldham JM, Riba MB series editors, American Psychiatric Publishing, Inc., Washington, DC, pp 123-227.
Gould TD, Zanos P, Zarate CA Jr (2017) Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology. 42, 368-369.
Zanos P, Moaddel R, Morris PJ, Albuquerque EX, Wainer IW, Thompson SM, Thomas CJ, Zarate CA Jr., Gould TD (2017) Reply to: Antidepressant actions of ketamine versus hydroxynorketamines. Biological Psychiatry. 81, e69-e71.
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr., Gould TD (2017) Reply to: Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 546, E4-E5.
Gould TD (2016) Irving I. Gottesman (1930-2016): The multifactorial threshold model of complex phenotypes mediated by endophenotype strategies. Genes, Brain, and Behavior. 15, 775-776.
Gould TD, Hashimoto R, Schulze TG (2016) Going longitudinal in biological psychiatric research: all things considered. Neuroscience Research. 102,1-3.
Gould TD, Can A, Gottesman II, Courtet P (2012) Differential lithium efficacy in reducing suicidal behaviors versus suicidal thoughts. American Journal of Psychiatry. 169, 98-99.
Gould TD and Einat H (2007) Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neuroscience and Biobehavioral Reviews. 31, 825-831.
Gould TD and Manji HK (2005) DARPP-32: a molecular switch at the nexus of reward pathway plasticity. Proceedings of the National Academy of Sciences of the United States of America. 102, 253-254.
Gould TD (2011) Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests. Volume II, 382 pages. Neuromethods Series, The Human Press Inc. Totowa, NJ.
Gould TD (2009) Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests. Volume I, 330 pages. Neuromethods Series, The Human Press Inc. Totowa, NJ.